Next Article in Journal
Do Young Elite Football Athletes Have the Same Strength and Power Characteristics as Senior Athletes?
Next Article in Special Issue
PKC Proteins and Muscular Dystrophy
Previous Article in Journal
Cognitive and Motivational Monitoring during Enriched Sport Activities in a Sample of Children Living in Europe. The Esa Program
Previous Article in Special Issue
Insights into the Pathogenic Secondary Symptoms Caused by the Primary Loss of Dystrophin
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview
J. Funct. Morphol. Kinesiol. 2017, 2(4), 47; https://doi.org/10.3390/jfmk2040047

Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy

1
Department of Experimental Medicine, University of Perugia, 06132 Perugia, Italy
2
Department of Medicine, University of Perugia, 06132 Perugia, Italy
3
Interuniversity Institute of Myology (IIM)
4
Centro Universitario di Ricerca sulla Genomica Funzionale, University of Perugia, 06132 Perugia, Italy
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 9 November 2017 / Revised: 11 December 2017 / Accepted: 13 December 2017 / Published: 15 December 2017
(This article belongs to the Special Issue Muscular Dystrophy)
View Full-Text   |   Download PDF [966 KB, uploaded 15 December 2017]   |  

Abstract

Duchenne muscular dystrophy (DMD) is a lethal X-linked pathology due to lack of dystrophin and characterized by progressive muscle degeneration, impaired locomotion and premature death. The chronic presence of inflammatory cells, fibrosis and fat deposition are hallmarks of DMD muscle tissue. Many different therapeutic approaches to DMD have been tested, including cell-based and gene-based approaches, exon skipping, induction of expression of the dystrophin paralogue, utrophin, and, most recently the application of the CASPR/Cas9 genome editing system. However, corticosteroid treatment remains the gold standard therapy, even if corticosteroids have shown multiple undesirable side effects. Sertoli cells (SeC) have long been known for their ability to produce immunomodulatory and trophic factors, and have been used in a plethora of experimental models of disease. Recently, microencapsulated porcine SeC (MC-SeC) injected intraperitoneally in dystrophic mice produced morphological and functional benefits in muscles thanks to their release into the circulation of anti-inflammatory factors and heregulin β1, a known inducer of utrophin expression, thus opening a new avenue in the treatment of DMD. In order to stress the potentiality of the use of MC-SeC in the treatment of DMD, here, we examine the principal therapeutic approaches to DMD, and the properties of SeC (either nude or encapsulated into alginate-based microcapsules) and their preclinical and clinical use. Finally, we discuss the potential and future development of this latter approach. View Full-Text
Keywords: Duchenne muscular dystrophy; therapeutic approaches; Sertoli cell; muscle inflammation; myopathies; encapsulation; biomaterials Duchenne muscular dystrophy; therapeutic approaches; Sertoli cell; muscle inflammation; myopathies; encapsulation; biomaterials
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Chiappalupi, S.; Salvadori, L.; Luca, G.; Riuzzi, F.; Calafiore, R.; Donato, R.; Sorci, G. Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy. J. Funct. Morphol. Kinesiol. 2017, 2, 47.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Funct. Morphol. Kinesiol. EISSN 2411-5142 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top